2023
Xylazine in the drug supply: Emerging threats and lessons learned in areas with high levels of adulteration
Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, Heimer R. Xylazine in the drug supply: Emerging threats and lessons learned in areas with high levels of adulteration. International Journal Of Drug Policy 2023, 120: 104154. PMID: 37574646, DOI: 10.1016/j.drugpo.2023.104154.Peer-Reviewed Original ResearchHarm reduction service providersDrug supplySedative-analgesic drugsFatal opioid overdosesOpioid overdose fatalitiesPresence of fentanylMedical examiner dataIllicit drug supplyInjection of xylazineFentanyl test stripsPrevention needsOpioid usersAnalgesic drugsOpioid overdosesOverdose deathsOverdose fatalitiesXylazineHealth threatSurvey of peopleDrugsSignificant predictorsFentanylConvenience surveyTest stripsTwo-thirds
2013
Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population.
Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. American Journal Of Public Health 2013, 104: 1713-21. PMID: 24134382, PMCID: PMC3990658, DOI: 10.2105/ajph.2013.301357.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis B virusDrug use durationSubstance abuse treatmentB virusRisk factorsCriminal justice involvementDrug usersAbuse treatmentAdult injection drug usersSeroprevalence of HIVInjection drug usePotential risk factorsSignificant predictorsUse durationMultiple viral infectionsEffective harm reduction strategiesHarm reduction strategiesJustice involvementHCV seroprevalenceInjection useInterim analysisViral infectionDrug useSerological tests